ProCE Banner Activity

AUGMENT-101: Phase I Study of Revumenib in Patients With KMT2A-Rearranged or NPM1-Mutant AML

Slideset Download
Conference Coverage

Phase I dose-finding study reports that treatment with revumenib, a menin inhibitor, resulted in a clinically manageable safety profile and deep, durable responses in patients with KMT2A or NPM1 acute leukemia.

Released: December 15, 2022

Expiration: December 14, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen